Related references
Note: Only part of the references are listed.Conscripts of the infinite armada: systemic cancer therapy using nanomaterials
David A. Scheinberg et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2010)
CD20-Targeted Therapy: The Next Generation of Antibodies
Tom van Meerten et al.
SEMINARS IN HEMATOLOGY (2010)
Challenges in monoclonal antibody-based therapies
Haritha Samaranayake et al.
ANNALS OF MEDICINE (2009)
MicroRNA Silencing in Primates: Towards Development of Novel Therapeutics
Andreas Petri et al.
CANCER RESEARCH (2009)
Ten years of rituximab in NHL
Matthew C. Winter et al.
EXPERT OPINION ON DRUG SAFETY (2009)
Antibody-based therapy of leukaemia
John C. Morris et al.
EXPERT REVIEWS IN MOLECULAR MEDICINE (2009)
Systemic administration of optimized aptamer-siRNA chimeras promotes regression of PSMA-expressing tumors
Justin P. Dassie et al.
NATURE BIOTECHNOLOGY (2009)
Serum Immunoglobulins and Risk of Infection: How Low Can You Go?
Daniel E. Furst
SEMINARS IN ARTHRITIS AND RHEUMATISM (2009)
Regulation of B-cell proliferation and differentiation by pre-B-cell receptor signalling
Sebastian Herzog et al.
NATURE REVIEWS IMMUNOLOGY (2009)
Assembling OX40 aptamers on a molecular scaffold to create a receptor-activating aptamer
Claudia M. Dollins et al.
CHEMISTRY & BIOLOGY (2008)
The design of polyvalent therapeutics
Amit Joshi et al.
CHEMISTRY-A EUROPEAN JOURNAL (2008)
Cell specific aptamer-photosensitizer conjugates as a molecular tool in photodynamic therapy
Prabodhika Mallikaratchy et al.
CHEMMEDCHEM (2008)
Multivalent 4-1BB binding aptamers costimulate CD8(+) T cells and inhibit tumor growth in mice
James O. McNamara et al.
JOURNAL OF CLINICAL INVESTIGATION (2008)
Clearance properties of nano-sized particles and molecules as imaging agents: considerations and caveats
Michelle Longmire et al.
NANOMEDICINE (2008)
Molecular assembly for high-performance bivalent nucleic acid inhibitor
Youngmi Kim et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
MicroRNAs as targets for antisense-based therapeutics
Jan Stenvang et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2008)
Aptamer directly evolved from live cells recognizes membrane bound immunoglobin heavy mu chain in Burkitt's lymphoma cells
Prabodhika Mallikaratchy et al.
MOLECULAR & CELLULAR PROTEOMICS (2007)
Perspectives on chemistry and therapeutic applications of Locked Nucleic Acid (LNA)
Harleen Kaur et al.
CHEMICAL REVIEWS (2007)
Tumor targeting with RGD peptide Ligands-Design of new molecular conjugates for Imaging and therapy of cancers
Elisabeth Garanger et al.
ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY (2007)
Selection of aptamers for molecular recognition and characterization of cancer cells
Zhiwen Tang et al.
ANALYTICAL CHEMISTRY (2007)
Optimization and modifications of aptamers selected from live cancer cell lines
Dihua Shangguan et al.
CHEMBIOCHEM (2007)
Altered B-cell receptor signaling kinetics distinguish human follicular lymphoma. B cells from tumor-infiltrating nonmalignant B cells
Jonathan M. Irish et al.
BLOOD (2006)
Recombinant antibodies: From the laboratory to the clinic
Huguette Albrecht et al.
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS (2006)
Biodistribution of phosphodiester and phosphorothioate siRNA
DA Braasch et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2004)
Expert review of non-Hodgkin's lymphomas in a population-based cancer registry: Reliability of diagnosis and subtype classifications
CA Clarke et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2004)
Application of locked nucleic acids to improve aptamer in vivo stability and targeting function
KS Schmidt et al.
NUCLEIC ACIDS RESEARCH (2004)
Mfold web server for nucleic acid folding and hybridization prediction
M Zuker
NUCLEIC ACIDS RESEARCH (2003)
Tenascin-C aptamers are generated using tumor cells and purified protein
BJ Hicke et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
Share Paper
